Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

Radocha, Jakub; Maisnar, Vladimír; Pour, Luděk; Špıčka, Ivan; Minařík, Jiří; Szeligová, Lenka; Pavlíček, Petr; Jungová, Alexandra; Krejčí, Marta; Pika, Tomáš; Štraub, Jan; Brožová, Lucie; Stejskal, Lukáš; Heindorfer, Adriana; Jindra, Pavel; Kessler, Petr; Mikula, Peter; Sýkora, Michal; Wróbel, Marek; Jarkovský, Jiří; Hájek, Roman

doi:10.1002/cam4.1620

Cited by 6 publications

(3 citation statements)

References 27 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are similar to studies conducted by Radocha et al 11,19 Beta 2 microglobulin levels were high in patients with t(4;14) with mean ± SD of 7.07 ± 3.64 and in patients without t(4;14) it was 4.096 ± 2.064, (p=0.029) and these results were comparable with study conducted by Radocha et al 19,5 In positive patients the mean ± SD of S albumin was 38.38 ± 7.99 and in negative patients it was 37.74 ± 5.598, there was statistically insignificant difference between S albumin and t(4;14) (p=0.786). These results does not matched with results of Radocha et al 19,5 Most of the patients with t(4;14) presented with advanced stage according to ISS scoring.Whereas in t(4;14) negative patients 30% were in stage I, 37% in stage II, and 33% in stage III. These results were comparable with results of study conducted by Ja min byun in which according toISS, 54 patients (33.5%) were in stage I, 61 (37.9%) in stageII and 46 (28.6%) in stage III.…”

Section: Discussionsupporting

confidence: 93%

Frequency of t(4;14) in Multiple Myeloma and Its Clinicopathological Correlation

Zaheer

Robert

Mahmood

et al. 2022

PAFMJ

View full text Add to dashboard Cite

Objective: To determine the frequency of t(4;14) in multiple myeloma in Pakistani population and study the clinicpathological correlation of this translocation in myeloma patients. Study Design: Cross sectional study. Place and Duration of Study: This study was conducted at Armed Forces Institute of Pathology from Jun 2017 to May 2018 using non probability convenience sampling technique. Methodology: A total of 53 newly diagnosed cases of multiple myeloma were included in the study. Patients were diagnosed as having multiple myeloma based on diagnostic criteria of international myeloma working group. Fish analysis was done for t (4; 14). Workup for end organ damage /myeloma defining events was done. Results: Out of 53 patients, 16 (30%) were females and 37(70%) were males; the mean age of the patients was 59.81 ± 11.34 range from 37 to 87 years. Fish for t(4;14) was positive in eight (15%) patients while negative in forty-five (85%) patients. Patients with positive results have significantly deranged renal function tests and raised beta 2 micoglobulins levels as compare to t(4;14)negative patients. Conclusions: Detection of t (4:14) in multiple myeloma patients not only has diagnostic value but is important in risk stratification of these patients and thus effect treatment decision.

show abstract

Section: Discussionsupporting

confidence: 93%

Frequency of t(4;14) in Multiple Myeloma and Its Clinicopathological Correlation

Zaheer

Robert

Mahmood

et al. 2022

PAFMJ

View full text Add to dashboard Cite

show abstract

“…A Czech study recently conducted to validate the R-ISS and IMWG scores found that the majority of NDMM patients were DSS III (70.3%) and 26.7% DSS B [ 14 ]. Similarly, a Turkish study found that in patients older than 65 years, 21% were ISS I, 37% ISS II and 42% ISS III.…”

Section: Discussionmentioning

confidence: 99%

Comparative survival analysis using the International Stratification Score (ISS) in newly-diagnosed multiple myeloma in the Uruguayan population

Garrido

Bove²,

Matosas

et al. 2021

Medicine and Pharmacy Reports

View full text Add to dashboard Cite

Background and aims. Multiple myeloma is a frequent hematologic malignancy, in which the International Stratification Score (ISS) is widely used to estimate the overall survival. However, there are no studies in Latin America evaluating its performance. This study aims to describe the ISS performance in the overall survival estimation for newly diagnosed multiple myeloma patients in Uruguay. Methods. This is a retrospective registry‐based survival analysis through the Grupo Uruguayo de Mieloma Múltiple (GUMMA) database, including newly diagnosed multiple myeloma patients from January 2001 until May 2019. Results. 249 patients were included, 51.81% males and an average age of 63.49 years. According to ISS and Durie-Salmon score (DSS), 47.79% and 82.3% were ISS III and DSS III, respectively. Also, 32.3% were DSS B. Auto hematopoietic stem cell transplantation was performed in 31.73% of patients, and bortezomib was used in 44.18% as frontline therapy. The overall survival was 80% for ISS1, 64.9% ISS2, and 48.6% ISS3 (Log-Rank; p <0.01). The average overall survival was 116.5 months for ISS 1, 77.6 months for ISS 2, and 57.8 months for ISS 3. The hazard ratio between ISS II and ISS I was 2.42 (95% CI 1.10-5.33; p<0.05), and 3.94 (95% CI 1.88-8.26; p<0.05) between ISS III and ISS II. Conclusion. The ISS staging system allows an adequate stratification of patients according to overall survival in the real-practice setting. However, considering the relevance of the new cytogenetic advances, it is necessary to increase the availability and quality of iFISH in Latin America.

show abstract

“…In a retrospective study, data from the Czech Myeloma Group Registry of Monoclonal Gammopathies was used to validate the IMWG frailty score and Revised International Staging System (R-ISS) indices for risk stratification in patients with MM in clinical practice. The results concluded that the prognostic value of the IMWG and R-ISS risk stratification indices apply to patients with MM in real-world settings ( 41 ).…”

Section: Geriatric Assessment and Vulnerability Scoresmentioning

confidence: 92%

Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects

2021

View full text Add to dashboard Cite

The increasing incidence of geriatric patients with multiple myeloma has elevated concerns in clinical practice. While the introduction of novel therapeutic agents has substantially improved outcomes in younger patients with myeloma, poorer outcomes remain in older patients. Managing older patients requires a multidisciplinary team approach to consider factors that may influence both treatment selection and outcomes. Aging is associated with remodeling of vital organs, physiological downregulations of basal metabolism, susceptibility to multiple comorbidities with ultimate frailty, thereby contributing to the underrepresentation and exclusion of very old patients from clinical trials. Therefore, timely confirmation of a precise diagnosis is crucial for prompt initiation of treatment if the desired outcome is to be achieved. Adequate and judicious assessment using comprehensive geriatric assessment tools minimizes toxicities and treatment discontinuation. Initiating treatment with combinational therapy requires knowledge of indications and anticipated outcomes, as well as individualized therapy with appropriate dose-adjustment. Individualized therapy based on good clinical acumen and best practices obverts unwanted polypharmacy, preventing iatrogenic harm. This review will therefore address the approaches and challenges faced in managing myeloma in geriatric patients aged 80 years and older, highlighting recommended therapeutic strategies and future prospective regimens.

show abstract

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

Cited by 6 publications

References 27 publications

Frequency of t(4;14) in Multiple Myeloma and Its Clinicopathological Correlation

Frequency of t(4;14) in Multiple Myeloma and Its Clinicopathological Correlation

Comparative survival analysis using the International Stratification Score (ISS) in newly-diagnosed multiple myeloma in the Uruguayan population

Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects

Contact Info

Product

Resources

About